TEVA
Teva Pharmaceutical Industries Ltd.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$41.31
−0.46%Aug 31, 2026, 16:41 UTC
Teva Pharmaceutical Industries has made a bid to acquire certain assets of BioXcel Therapeutics, including the product Igalmi and a potential at-home agitation treatment, to expand its neuroscience portfolio.
Source:Aug 28, 2026, 10:00 UTC
BioXcel Therapeutics entered into an asset sale agreement with Teva Pharmaceuticals, which will act as the stalking horse bidder in a court-supervised 363 auction process.
Aug 25, 2026, 13:43 UTC
Turkey's Competition Board (Rekabet Kurumu) launched an antitrust investigation into Teva Pharmaceutical for allegedly manipulating the patent system and disparaging rival drugs to hinder market entry.
Source:Aug 21, 2026, 13:06 UTC
Turkey has initiated an antitrust investigation into Teva Pharmaceutical Industries.
Source:Aug 20, 2026, 17:41 UTC
Teva's ecopipam received FDA priority review designation for pediatric Tourette syndrome, potentially the first new therapy in over a decade.
Source:Aug 19, 2026, 20:05 UTC
Aurinia Pharmaceuticals settled patent litigation with Teva Pharmaceuticals, resolving the dispute between the two companies.
Aug 19, 2026, 13:23 UTC
President Trump is expected to nominate Heidi Overton, deputy director of domestic policy for the White House, to serve as the next commissioner of the U.S. Food and Drug Administration.
Aug 19, 2026, 12:31 UTC
Teva announced that its Ecopipam Phase 3 clinical trial reduced relapse risk by 53%.
Source:Aug 19, 2026, 12:30 UTC
The U.S. FDA accepted Teva's New Drug Application for ecopipam and granted priority review for treating pediatric Tourette syndrome, with a PDUFA date in late Q1 2027.
Source:Aug 6, 2026, 16:22 UTC
Teva Pharmaceuticals asked a U.S. judge to prevent insurer Humana from telling jurors it is an Israeli company at a drug price-fixing trial, citing potential prejudice from Gaza war views.
Jul 29, 2026, 17:57 UTC
Teva Pharmaceutical Industries announced the replacement of its American Depositary Share program with a direct listing of its ordinary shares on the New York Stock Exchange, with trading commencing on September 14, 2026.
Source:Jul 15, 2026, 16:15 UTC
Medincell completed non-dilutive financing transactions including securing €28 million in new bank loans and repaying €20 million of its European Investment Bank credit facility, extending overall debt maturity to mid-2031.
Source:Jul 14, 2026, 13:16 UTC
A U.S. appeals court revived a lawsuit by Teva Pharmaceuticals accusing Eli Lilly of breaching a settlement agreement that allowed Teva to market a generic version of Lilly's osteoporosis drug Forteo.
Source:Jul 12, 2026, 22:02 UTC
Teva Pharmaceutical Industries announced encouraging 24-week efficacy results from a phase 1b proof-of-concept study of its anti-IL-15 antibody for vitiligo, highlighting the program as part of its shift toward a biopharma-focused growth strategy.
Source:Jul 9, 2026, 13:00 UTC
Teva and Polpharma Biologics announced a global licensing agreement for a biosimilar candidate to Ocrevus (ocrelizumab) for multiple sclerosis.
Source:Jul 1, 2026, 12:30 UTC
The U.S. Supreme Court unanimously ruled in favor of generic drug manufacturers in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., reversing the Federal Circuit and setting a new standard for induced patent infringement claims.
Source:Jun 18, 2026, 20:57 UTC
Teva Pharmaceutical Industries submitted a New Drug Application (NDA) to the U.S. FDA for ecopipam, a therapy for pediatric Tourette syndrome.
Source:Jun 10, 2026, 16:03 UTC
Teva Pharmaceutical Industries closed its acquisition of Emalex Biosciences, strengthening its late-stage neuroscience pipeline with ecopipam.
Source:
← PreviousPage 2